Marzola P, Maggioni F, Vicinanza E, Daprà M, Cavagna F M
Milano Research Centre, Bracco SpA, Italy.
J Magn Reson Imaging. 1997 Jan-Feb;7(1):147-52. doi: 10.1002/jmri.1880070121.
This work was conducted to test the hypothesis that contrast-enhanced MRI with hepatocyte-specific contrast agents facilitates quantitation and mapping of diffuse liver diseases such as hepatitis and cirrhosis. Gadobenate dimeglumine (Gd-BOPTA/Dimeg, Bracco SpA, Millano, Italy) is a new paramagnetic hepatocyte-specific contrast agent currently undergoing clinical trials. We have assessed the usefulness of gadobenate dimeglumine for the diagnosis of diffuse liver diseases in a rat model of chemically induced hepatitis. The study was based on the measurements of in vivo liver relaxation times as well as on the acquisition of standard SE images. Acute hepatitis considerably reduced the degree of T1 shortening of liver parenchyma caused by intravenous injection of .25 mmol/kg of gadobenate dimeglumine. Analogously, the enhancement of the MRI signal intensity of the liver of rats with hepatitis observed in T1-weighted spin-echo (SE) images was inferior, in terms of both strength and duration, to that recorded in control rats at doses of .25 mmol/kg and .075 mmol/kg of gadobenate dimeglumine. Our results show that gadobenate dimeglumine-enhanced MR imaging has the potential for visualization of hepatitis and for assessment of liver function. Our conclusions differ from those previously published on this subject by other authors. The reasons that led to differing conclusions are discussed.
使用肝细胞特异性造影剂的对比增强磁共振成像（MRI）有助于对肝炎和肝硬化等弥漫性肝病进行定量分析和成像。钆贝葡胺（Gd - BOPTA/二葡甲胺，意大利米兰的博莱科公司）是一种新型顺磁性肝细胞特异性造影剂，目前正在进行临床试验。我们在化学诱导肝炎的大鼠模型中评估了钆贝葡胺对弥漫性肝病的诊断价值。该研究基于体内肝脏弛豫时间的测量以及标准SE图像的采集。急性肝炎显著降低了静脉注射0.25 mmol/kg钆贝葡胺引起的肝实质T1缩短程度。类似地，在T1加权自旋回波（SE）图像中观察到的肝炎大鼠肝脏MRI信号强度增强，在强度和持续时间方面均低于注射0.25 mmol/kg和0.075 mmol/kg钆贝葡胺的对照大鼠。我们的结果表明，钆贝葡胺增强磁共振成像有可视化肝炎和评估肝功能的潜力。我们的结论与其他作者此前发表的关于该主题的结论不同。文中讨论了导致结论不同的原因。
